Approval · Notice of Compliance 16935 · 2015
ATRIANCE: Notice of Compliance 16935
Issued May 7, 2015
A Notice of Compliance is Health Canada’s approval of a drug submission: a new drug, a new use or form, or a change to an approved one. The product itself is in the Drug Product Database, with its current status.
- Notice number
- 16935
- Date
- May 7, 2015
- Company
- Glaxosmithkline IncMississauga, Ontario, Canada
- Product type
- Prescription Pharmaceutical
- Submission
- Supplement to a New Drug Submission (SNDS), supplement
- Submission class
- Other
- Reason
- To register a replacement stopper (primary container closure) for the drug product
- Therapeutic class
- Antineoplastic agent
Products in this notice
| Brand | DIN | Status today |
|---|---|---|
| ATRIANCE | Not yet assigned | — |
Medicinal ingredients
- NELARABINE 5 MG per ML